Global Hepatitis Drug Market to Cross 70 Bn by 2023, Expects Kuick Research in Its New Report Recently Added at MarketPublishers.com

10 Jul 2017 • by Natalie Aster

LONDON – Nowadays, hepatitis is one of the primary public health threats worldwide; it is recognized as the key reason for the development of hepatocellular carcinoma and liver cirrhosis. The incidence of hepatitis is increasing every year.

The past 2 decades have seen remarkable progress in hepatitis treatment, including the introduction of interferons, nucleoside analogues, protease inhibitors and toll like receptors, which revolutionized hepatitis management.

With the recent considerable progress in development of protein antiviral drugs for chronic hepatitis virus infection, virological responses are observed in almost all patients. Today, the treatment with antiviral agents is strongly recommended, the main purpose of such treatment is to inhibit the hepatitis virus replication and also to improve the liver pathology; however, it rarely cures the chronic infection.

The value of the world’s hepatitis drug market is anticipated to cross USD 70 billion by the year 2023, propelled by the escalating number of infected population, rising consumption of drugs and alcohol, and constantly improving access to hepatitis medicine, among other drivers.

The introduction of generic drugs in the hepatitis drug market has also an important impact on the market dynamics worldwide. In the wake of increasing number of people able to afford the generic versions, the drugs usage rates are likely to surge in the years ahead.

Today, there are 321 drugs in hepatitis clinical pipeline and 110 hepatitis drugs are already commercially available.

The new report “Global Hepatitis Drug Market & Clinical Trials Insight 2023” worked out by Kuick Research is an essential source of trustworthy info on the world’s hepatitis drug market performance and on the hepatitis clinical pipeline and trials. Besides, the report presents an insightful coverage of the hepatitis infection prevalence, reviews the available drug classes, offers data on the key market segments depending on the hepatitis type, gives info on the marketed drugs by drug class, and also discusses the future perspective of hepatitis therapeutics.

For other in-demand research reports by this publisher follow to the Kuick Research page.

CONTACTS

The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970
ps@marketpublishers.com
MarketPublishers.com